The estimated Net Worth of Carl Decicco is at least $4.04 Milión dollars as of 9 December 2021. Dr Decicco owns over 104,310 units of Foghorn Therapeutics stock worth over $3,362,294 and over the last 4 years he sold FHTX stock worth over $0. In addition, he makes $676,240 as Chief Scientific Officer at Foghorn Therapeutics.
Dr has made over 2 trades of the Foghorn Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 104,310 units of FHTX stock worth $388,033 on 9 December 2021.
The largest trade he's ever made was exercising 104,310 units of Foghorn Therapeutics stock on 9 December 2021 worth over $388,033. On average, Dr trades about 36,603 units every 136 days since 2020. As of 9 December 2021 he still owns at least 362,707 units of Foghorn Therapeutics stock.
You can see the complete history of Dr Decicco stock trades at the bottom of the page.
Dr. Carl Peter Decicco Ph.D. is the Chief Scientific Officer at Foghorn Therapeutics.
As the Chief Scientific Officer of Foghorn Therapeutics, the total compensation of Dr D at Foghorn Therapeutics is $676,240. There are no executives at Foghorn Therapeutics getting paid more.
Dr D is 61, he's been the Chief Scientific Officer of Foghorn Therapeutics since . There are no older and 6 younger executives at Foghorn Therapeutics.
Carl's mailing address filed with the SEC is 500 TECHNOLOGY SQUARE, STE 700, CAMBRIDGE, MA, 02139.
Over the last 4 years, insiders at Foghorn Therapeutics have traded over $262,160 worth of Foghorn Therapeutics stock and bought 305,500 units worth $4,888,000 . The most active insiders traders include Adam Koppel, Ian F Smith a B Lynne Parshall. On average, Foghorn Therapeutics executives and independent directors trade stock every 109 days with the average trade being worth of $663,343. The most recent stock trade was executed by Steven F. Bellon on 9 September 2024, trading 20,000 units of FHTX stock currently worth $190,000.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. Foghorn Therapeutics Inc. has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel therapeutics based on disruptors of a specified transcription factor target. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Foghorn Therapeutics executives and other stock owners filed with the SEC include: